Neal D. Shore, MD, FACS

Articles

Dr. Shore on the FDA Approval of Relugolix in Advanced Prostate Cancer

December 18th 2020

Neal D. Shore, MD, FACS, discusses the approval of relugolix in advanced prostate cancer.

Dr. Shore on the Need for Further Education on Molecular Testing in mCRPC

October 29th 2020

Neal D. Shore, MD, FACS, discusses the need for further education on molecular testing for metastatic castration-resistant prostate cancer.

Dr. Shore on Unique Challenges in Nonmetastatic CRPC

August 3rd 2020

Neal D. Shore, MD, FACS, discusses unique challenges in nonmetastatic castration-resistant prostate cancer.

Dr. Shore on Cardio-Oncology Strategies in Prostate Cancer

July 30th 2020

Neal D. Shore, MD, FACS, discusses the cardio-oncology strategies that can be implemented in patients with prostate cancer to reduce the chances of a cardio-related adverse-event.

Dr. Shore on the Safety Profiles of Relugolix and Leuprolide in Prostate Cancer

July 1st 2020

​Neal D. Shore, MD, FACS, discusses the safety profiles of relugolix and leuprolide in advanced prostate cancer.

Dr. Shore on Immunotherapy Targeting PSA and PSMA in Biochemically Recurrent Prostate Cancer

June 22nd 2020

Neal D. Shore, MD, FACS, discusses immunotherapy targeting prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) in biochemically recurrent prostate cancer.

Dr. Shore on the Rationale for the Phase 3 HERO Trial in Advanced Prostate Cancer

June 22nd 2020

​Neal D. Shore, MD, FACS, discusses the rationale for conducting the phase 3 HERO trial in advanced prostate cancer.

Dr. Neal Shore on Treatment of Elderly Patients With mCRPC

September 14th 2016